SLC1A5 and colorectal carcinoma: In addition, pharmacological inhibitors of AATs (JPH203 and V‐9302) as well as specific knockdowns of SLC1A5/ASCT2, SLC7A5/LAT1, and SLC38A2/SNAT2 significantly reduced amino acid transport, which decreased CRC proliferation via inhibition of mTOR activation (Figs. 4A–D and 5A–D).